Why Global Blood Therapeutics Is Rallying Today
Shares of hematology biotech Global Blood Therapeutics (NASDAQ: GBT) are up 16.5% as of 10:30 a.m. EDT after the company posted upbeat second-quarter 2021 earnings. Sales of its sickle cell disease drug Oxbryta shot up 51% year over year to $47.6 million.
In a recent survey of 278 physicians, nearly all prescribers were satisfied with using the drug for disease control. SCD is a severe hereditary disease that causes distortions in blood hemoglobin. The irregularly shaped red blood cells can then block blood vessels, causing a life-threatening condition called a vaso-occlusive crisis.
Source Fool.com